pirfenidone has been researched along with Sclerosis, Systemic in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 6 (35.29) | 2.80 |
| Authors | Studies |
|---|---|
| Bailie, M; Campbell, PL; Dexheimer, T; Fox, DA; Haak, AJ; Hutchings, KM; Kahl, DJ; Khanna, D; Larsen, SD; Leipprandt, JR; Lisabeth, EM; Neubig, RR; Sun, D; Tsou, PS; Wen, B | 1 |
| Adnot, S; Bischof, O; Lipskaia, L | 1 |
| Distler, O; Hoffmann-Vold, AM; Maher, TM; Volkmann, ER | 1 |
| Acharya, N; Dhir, V; Dhooria, S; Jain, S; Mishra, D; Sharma, SK | 1 |
| Li, G; Nong, L; Wang, M; Wang, R | 1 |
| McMahan, ZH; Volkmann, ER | 1 |
| Altinisik, G; Karasu, U; Ufuk, F | 1 |
| Allard, B; Batteux, F; Blanco, P; Chizzolini, C; Constans, J; Contin-Bordes, C; Duffau, P; Forcade, E; Groppi, A; Henrot, P; Izotte, J; Jeljeli, M; Jolivel, V; Laurent, P; Lazaro, E; Leleu, D; Levionnois, E; Manicki, P; Pradeu, T; Richez, C; Schaeverbeke, T; Seneschal, J; Truchetet, ME | 1 |
| Chen, Z; Li, XJ; Liao, XP; Lin, H; Xiao, H; Zhang, GF; Zhang, J; Zhang, X | 1 |
| George, PM; Wells, AU | 1 |
| Bergmann, C; Distler, JH | 1 |
| Albera, C; Chen, D; Chung, L; Fischer, A; Gorina, E; Khalidi, N; Khanna, D; Raghu, G; Schiopu, E; Seibold, JR; Tagliaferri, M | 1 |
| Bi, YL; Feng, RE; Huang, H; Li, S; Xu, K; Xu, ZJ | 1 |
| Günther, A; Markart, P; von der Beck, D | 1 |
| Lota, HK; Wells, AU | 1 |
| Hamada, K; Izumi, T; Nagai, S; Shigematsu, M; Taniyama, M; Yamauchi, S | 1 |
| Antoniu, SA | 1 |
5 review(s) available for pirfenidone and Sclerosis, Systemic
| Article | Year |
|---|---|
Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease.
Topics: Antibodies, Monoclonal, Humanized; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lung Diseases, Interstitial; Lung Transplantation; Pyridones; Randomized Controlled Trials as Topic; Rituximab; Scleroderma, Systemic; Transplantation, Autologous | 2019 |
An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis.
Topics: Autoantibodies; Clinical Trials as Topic; Cyclophosphamide; Drugs, Investigational; Humans; Lung Diseases, Interstitial; Mycophenolic Acid; Pyridones; Rituximab; Scleroderma, Diffuse; Scleroderma, Systemic; Treatment Outcome | 2020 |
[Interstitial lung disease].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Guidelines as Topic; Humans; Lung Diseases, Interstitial; Lymphangioleiomyomatosis; Pyridones; Sarcoidosis; Scleroderma, Systemic | 2011 |
The evolving pharmacotherapy of pulmonary fibrosis.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Interstitial Pneumonias; Immunosuppressive Agents; Indoles; Lung Diseases, Interstitial; Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Sarcoidosis, Pulmonary; Scleroderma, Systemic; Treatment Outcome | 2013 |
Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Topics: Administration, Oral; Amiodarone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Cell Line; Clinical Trials, Phase II as Topic; Connective Tissue Growth Factor; Cricetinae; Cyclophosphamide; Drug Evaluation, Preclinical; Drugs, Investigational; Fibroblasts; Hermanski-Pudlak Syndrome; Humans; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Lung Transplantation; Mice; Orphan Drug Production; Photosensitivity Disorders; Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Transforming Growth Factor beta; Treatment Outcome; Tumor Necrosis Factor-alpha | 2006 |
2 trial(s) available for pirfenidone and Sclerosis, Systemic
| Article | Year |
|---|---|
Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial.
Topics: Adult; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Lung Diseases, Interstitial; Male; Middle Aged; Pilot Projects; Pyridones; Scleroderma, Systemic; Treatment Outcome; Vital Capacity | 2020 |
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Mycophenolic Acid; Pyridones; Scleroderma, Systemic; Treatment Outcome | 2016 |
10 other study(ies) available for pirfenidone and Sclerosis, Systemic
| Article | Year |
|---|---|
5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma.
Topics: Animals; Carboxylic Acids; Connective Tissue Growth Factor; Enzyme Inhibitors; Female; Fibrosis; Mice, Inbred C57BL; Microsomes, Liver; Molecular Structure; Oxadiazoles; rho GTP-Binding Proteins; Scleroderma, Systemic; Serum Response Factor; Signal Transduction; Skin; Structure-Activity Relationship; Trans-Activators; Transcription, Genetic | 2019 |
What is hidden behind a pulmonary hypertensive, fibrotic and inflammatory phenotype?
Topics: Animals; Mice; Phenotype; Pulmonary Fibrosis; Pyridones; Scleroderma, Systemic | 2022 |
Multiple eruptive dermatofibromas aggravated by mycophenolate mofetil and pirfenidone in a patient with systemic sclerosis.
Topics: Antirheumatic Agents; Female; Histiocytoma, Benign Fibrous; Humans; Lung Diseases, Interstitial; Middle Aged; Mycophenolic Acid; Pyridones; Scleroderma, Systemic; Skin; Skin Neoplasms | 2020 |
Pleuroparenchymal fibroelastosis in a patient with systemic sclerosis.
Topics: Aged; Bronchiectasis; Disease Progression; Elastic Tissue; Female; Humans; Lung Diseases, Interstitial; Pleural Diseases; Pulmonary Diffusing Capacity; Pulmonary Fibrosis; Pyridones; Scleroderma, Systemic; Tomography, X-Ray Computed; Vital Capacity | 2021 |
TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Cell Differentiation; Collagen; Disease Models, Animal; Female; Fibroblasts; Fibrosis; Gene Expression Profiling; Humans; Interleukin-10; Lectins, C-Type; Lymphocytes; Male; Mice; Middle Aged; Myofibroblasts; Pyridones; Receptors, Immunologic; Scleroderma, Systemic; Skin; Transforming Growth Factor beta | 2021 |
Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease.
Topics: Actins; Adult; Case-Control Studies; Cells, Cultured; Female; Fibroblasts; Fibronectins; Glycogen Synthase Kinase 3 beta; Hedgehog Proteins; Humans; Lung; Lung Diseases, Interstitial; Male; MAP Kinase Kinase 4; Middle Aged; Nuclear Proteins; Patched-1 Receptor; Phosphorylation; Pulmonary Fibrosis; Pyridones; Repressor Proteins; Scleroderma, Systemic; Signal Transduction; Smad2 Protein; Tomography, X-Ray Computed; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2018 |
Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy.
Topics: Evidence-Based Medicine; Humans; Immunosuppressive Agents; Immunotherapy; Indoles; Lung Diseases, Interstitial; Phenotype; Pyridones; Risk Assessment; Scleroderma, Systemic | 2018 |
[Systemic sclerosis - an update].
Topics: Algorithms; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Endothelin Receptor Antagonists; Guanylate Cyclase; Humans; Hypertension, Pulmonary; Indoles; Pulmonary Artery; Pyrazoles; Pyridones; Pyrimidines; Rituximab; Scleroderma, Systemic; Sulfonamides | 2015 |
A case report: The efficacy of pirfenidone in a Chinese patient with progressive systemic sclerosis-associated interstitial lung disease: A CARE-compliant article.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Lung Diseases, Interstitial; Middle Aged; Pyridones; Scleroderma, Systemic; Treatment Outcome | 2016 |
Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Gas Analysis; Chronic Disease; Feasibility Studies; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Pulmonary Fibrosis; Pyridones; Radiography, Thoracic; Respiratory Function Tests; Scleroderma, Systemic; Time Factors; Treatment Outcome | 2002 |